AMG 900(口服泛极光激酶抑制剂)治疗成人急性髓系白血病的1期研究
这项1期研究评估了口服泛极光激酶抑制剂AMG 900在拒绝标准治疗或复发/难治的急性髓系白血病(AML)成人患者中的安全性和疗效。35例患者接受两种每2周给药方案(4/10方案22例,7/7方案13例),常见治疗相关不良事件为恶心(31%)、腹泻(29%)、发热性中性粒细胞减少(29%)和乏力(23%),3例(9%)达到血细胞计数未完全恢复的完全缓解。探索性生物标志物分析显示,基线BIRC5、AURKA、TTK、CDC2和CCNB1等通路相关基因表达较高的患者更可能应答。
要点
- AMG 900在AML患者中两种每2周给药方案均可耐受。
- 3例(9%)达到血细胞计数未完全恢复的完全缓解。
- 基线BIRC5、AURKA、TTK、CDC2、CCNB1表达较高者更可能应答。
核心结论
- AMG 900在总体AML人群中可耐受,通路特异性生物标志物识别出潜在的目标人群。
- 未来的研究将致力于进一步探索应答生物标志物以及AMG 900与其他抗癌药物的联合。
研究设计与样本
- 这是一项1期研究,采用改良3+3+3设计评估两种每2周剂量递增方案。
- 入组标准为经病理学证实的AML患者,且拒绝标准治疗或既往治疗后复发或难治。
- 共入组35例患者,覆盖9个不同剂量水平:4/10方案(每日给药4天、休息10天)22例,日剂量15至100 mg;7/7方案(每日给药7天、休息7天)13例,日剂量30至50 mg。
主要发现
- 两种方案均可耐受;最常见的治疗相关不良事件为恶心(31%)、腹泻(29%)、发热性中性粒细胞减少(29%)和乏力(23%)。
- 3例患者(9%)达到血细胞计数未完全恢复的完全缓解。
- 探索性生物标志物分析显示,基线BIRC5、AURKA、TTK、CDC2和CCNB1等特定通路相关基因表达较高的患者更可能应答。
关键数值与推荐
- 4/10方案日剂量范围为15至100 mg,7/7方案日剂量范围为30至50 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aurora kinases are involved in the pathophysiology of several cancers including acute myeloid leukemia (AML). In this phase 1 study, we investigated the safety and efficacy of AMG 900, an orally administered, highly potent, selective, small-molecule inhibitor of both Aurora kinase A and B, in patients with AML . Patients with pathologically documented AML who either declined standard treatments or had relapsed from or were refractory to previous therapies were enrolled. Two every-2-week dose-escalation schedules using a modified 3 + 3 + 3 design were evaluated AMG 900 given daily for 4 days with 10 days off (4/10 schedule), and AMG 900 given daily for 7 days with 7 days off (7/7 schedule). Thirty-five patients were enrolled at 9 different dose levels: 22 patients on the 4/10 schedule (doses from 15 to 100 mg daily), and 13 patients on the 7/7 schedule (doses from 30 to 50 mg daily). Both schedules were tolerated; nausea (31%), diarrhea (29%), febrile neutropenia (29%), and fatigue (23%) were the most common treatment-related adverse events. Three patients (9%) achieved complete response with incomplete count recovery. Patients with higher baseline expression of a set of specific pathway-related genes (BIRC5, AURKA, TTK, CDC2, and CCNB1) were more likely to respond in an exploratory biomarker analysis. AMG 900 was tolerated in a general AML population, and pathway-specific biomarkers identified a potential target population. Future research efforts will be directed toward further exploration of biomarkers of response and combination of AMG 900 with other anticancer agents.
引用
- Kantarjian HM, Schuster MW, Jain N, et al. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia. Am J Hematol. 2017. PMID: 28370201. doi:10.1002/ajh.24736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。